{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T21:10:21Z","timestamp":1792444221044,"version":"4.5.0"},"reference-count":41,"publisher":"European Respiratory Society (ERS)","issue":"4","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["ERJ Open Res"],"accepted":{"date-parts":[[2026,3,16]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bronchiectasis is a chronic, inflammatory lung disease with distinct endotypes, often defined by inflammatory cells in blood and sputum. We assessed safety and efficacy of benralizumab, an anti-interleukin-5R\u03b1 monoclonal antibody, in patients with bronchiectasis and eosinophilic inflammation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      MAHALE (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT05006573\">NCT05006573<\/jats:ext-link>\n                      ) was a 52-week, randomised, multicentre, double-blind, phase 3 study. Patients with bronchiectasis and no comorbid pulmonary conditions were randomised 1:1 to receive subcutaneous benralizumab 30\u2005mg or placebo every 4\u2005weeks. Primary end-point was annualised exacerbation rate. Secondary end-points included: time to first exacerbation, change from baseline in respiratory symptoms, lung function, health-related quality of life (HRQoL), respiratory health status and safety. In August 2022, the study was terminated early due to recruitment challenges related to the COVID-19 pandemic.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      100 patients were randomised and 99 were dosed (benralizumab, n=54; placebo, n=45); 21 had blood eosinophil counts \u2265300\u2005cells\u00b7\u00b5L\n                      <jats:sup>\u22121<\/jats:sup>\n                      . Notable imbalances in baseline characteristics between treatment arms suggested patients receiving benralizumab had more severe disease. The study did not enrol enough patients to meet power requirement to detect differences in efficacy end-points between benralizumab and placebo. At the end of the study, annualised exacerbation rates were not significantly different between treatment groups (rate ratio (95% confidence interval): 1.14 (0.71\u20131.82), p=0.59). Change in respiratory symptoms and HRQoL were similar between treatment groups. Benralizumab was well tolerated.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      A small sample size with eosinophil counts predominantly &lt;300 cells\u00b7\u00b5L\n                      <jats:sup>\u22121<\/jats:sup>\n                      and imbalances at baseline limit interpretation of data on clinical outcomes following benralizumab treatment. Adequately powered randomised trials are needed in the population of interest.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1183\/23120541.01529-2025","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T14:55:12Z","timestamp":1777647312000},"page":"01529-2025","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Benralizumab in bronchiectasis: results from the phase 3 MAHALE study"],"prefix":"10.1183","volume":"12","author":[{"given":"James D.","family":"Chalmers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0090-4531","authenticated-orcid":false,"given":"Stefano","family":"Aliberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Burr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulla M\u00f8ller","family":"Weinreich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel \u00c1ngel","family":"Bergna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"\u00c5strand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashanth","family":"Basavanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maura","family":"Gatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3360-9651","authenticated-orcid":false,"given":"Calvin N.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Ivanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"McCrae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Rom\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svitlana","family":"Salemio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Jison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2026,5,1]]},"reference":[{"key":"2026082403352343000_12.4.01529-2025.1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01033-2015"},{"key":"2026082403352343000_12.4.01529-2025.2","doi-asserted-by":"crossref","first-page":"20241009","DOI":"10.1183\/16000617.0091-2024","article-title":"Epidemiology of bronchiectasis","volume":"33","author":"Nigro","year":"2024","journal-title":"Eur Respir Rev"},{"key":"2026082403352343000_12.4.01529-2025.3","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00518-2024"},{"key":"2026082403352343000_12.4.01529-2025.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31767-7"},{"key":"2026082403352343000_12.4.01529-2025.5","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201507-472OC"},{"key":"2026082403352343000_12.4.01529-2025.6","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S2213-2600(21)00277-0","article-title":"Criteria and definitions for the radiological and clinical diagnosis of bronchiectasis in adults for use in clinical trials: international consensus recommendations","volume":"10","author":"Aliberti","year":"2022","journal-title":"Lancet Respir Med"},{"key":"2026082403352343000_12.4.01529-2025.7","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00629-2017"},{"key":"2026082403352343000_12.4.01529-2025.8","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00051-2017"},{"key":"2026082403352343000_12.4.01529-2025.9","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2014-205918"},{"key":"2026082403352343000_12.4.01529-2025.10","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00057306"},{"key":"2026082403352343000_12.4.01529-2025.11","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01126-2025"},{"key":"2026082403352343000_12.4.01529-2025.12","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201711-2202OC"},{"key":"2026082403352343000_12.4.01529-2025.13","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/642503"},{"key":"2026082403352343000_12.4.01529-2025.14","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01333-2019"},{"key":"2026082403352343000_12.4.01529-2025.15","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202108-1889OC"},{"key":"2026082403352343000_12.4.01529-2025.16","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cyto.2017.08.005","article-title":"The role of non-invasive modalities for assessing inflammation in patients with non-cystic fibrosis bronchiectasis","volume":"99","author":"Tsikrika","year":"2017","journal-title":"Cytokine"},{"key":"2026082403352343000_12.4.01529-2025.17","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00328-2018"},{"key":"2026082403352343000_12.4.01529-2025.18","doi-asserted-by":"crossref","first-page":"20420986241279213","DOI":"10.1177\/20420986241279213","article-title":"Safety profile of drugs used in non-cystic fibrosis bronchiectasis: a narrative review","volume":"15","author":"Upadhyay","year":"2024","journal-title":"Ther Adv Drug Saf"},{"key":"2026082403352343000_12.4.01529-2025.19","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.chest.2023.04.029","article-title":"The U-shaped relationship between eosinophil count and bronchiectasis severity: the effect of inhaled corticosteroids","volume":"164","author":"Martinez-Garcia","year":"2023","journal-title":"Chest"},{"key":"2026082403352343000_12.4.01529-2025.20","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00408-023-00668-w","article-title":"Elevated eosinophil counts in acute exacerbations of bronchiectasis: unveiling a distinct clinical phenotype","volume":"202","author":"Chen","year":"2024","journal-title":"Lung"},{"key":"2026082403352343000_12.4.01529-2025.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2010.04.004"},{"key":"2026082403352343000_12.4.01529-2025.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2016.01.003"},{"key":"2026082403352343000_12.4.01529-2025.23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31322-8"},{"key":"2026082403352343000_12.4.01529-2025.24","unstructured":"European Medicines Agency . Fasenra summary of product characteristics. 2025. Date last accessed: 18 February 2025. www.ema.europa.eu\/en\/documents\/product-information\/fasenra-epar-product-information_en.pdf"},{"key":"2026082403352343000_12.4.01529-2025.25","unstructured":"US Food and Drug Administration . Fasenra prescribing information. 2024. Date last accessed: 18 February 2025. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761070s021lbl.pdf"},{"key":"2026082403352343000_12.4.01529-2025.26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2311155"},{"key":"2026082403352343000_12.4.01529-2025.27","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1111\/bcp.16087","article-title":"Pharmacokinetics\/pharmacodynamics of benralizumab in chronic rhinosinusitis with nasal polyps: Phase III, randomized, placebo-controlled OSTRO trial","volume":"90","author":"Emson","year":"2024","journal-title":"Br J Clin Pharmacol"},{"key":"2026082403352343000_12.4.01529-2025.28","doi-asserted-by":"crossref","first-page":"772","DOI":"10.3390\/biomedicines9070772","article-title":"T2-high endotype and response to biological treatments in patients with bronchiectasis","volume":"9","author":"Oriano","year":"2021","journal-title":"Biomedicines"},{"key":"2026082403352343000_12.4.01529-2025.29","doi-asserted-by":"publisher","DOI":"10.1111\/resp.12702"},{"key":"2026082403352343000_12.4.01529-2025.30","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.chest.2022.08.2240","article-title":"Sex and gender in lung diseases and sleep disorders: a state-of-the-art review: part 2","volume":"163","author":"Sodhi","year":"2023","journal-title":"Chest"},{"key":"2026082403352343000_12.4.01529-2025.31","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2017-210983.48"},{"key":"2026082403352343000_12.4.01529-2025.32","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01953-2017"},{"key":"2026082403352343000_12.4.01529-2025.33","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1177\/19458924211009429","article-title":"A phase II, multicenter, randomized, placebo-controlled study of benralizumab, a humanized anti-IL-5R alpha monoclonal antibody, in patients with eosinophilic chronic rhinosinusitis","volume":"35","author":"Takabayashi","year":"2021","journal-title":"Am J Rhinol Allergy"},{"key":"2026082403352343000_12.4.01529-2025.34","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S2213-2600(17)30190-X","article-title":"Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"5","author":"Ferguson","year":"2017","journal-title":"Lancet Respir Med"},{"key":"2026082403352343000_12.4.01529-2025.35","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jaci.2021.08.030","article-title":"Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: a randomized, placebo-controlled trial","volume":"149","author":"Bachert","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"2026082403352343000_12.4.01529-2025.36","doi-asserted-by":"crossref","first-page":"F1000 Faculty Rev-293","DOI":"10.12688\/f1000research.17295.1","article-title":"Bronchiectasis insanity: doing the same thing over and over again and expecting different results?","volume":"8","author":"Metersky","year":"2019","journal-title":"F1000Res"},{"key":"2026082403352343000_12.4.01529-2025.37","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00160508"},{"key":"2026082403352343000_12.4.01529-2025.38","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.156.2.9607083"},{"key":"2026082403352343000_12.4.01529-2025.39","doi-asserted-by":"crossref","first-page":"580","DOI":"10.4168\/aair.2023.15.5.580","article-title":"Real-world investigation of eosinophilic-associated disease overlap (REVEAL): analysis of a US claims database","volume":"15","author":"Brailean","year":"2023","journal-title":"Allergy Asthma Immunol Res"},{"key":"2026082403352343000_12.4.01529-2025.40","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1164\/rccm.202309-1614OC","article-title":"The association between bronchiectasis and chronic obstructive pulmonary disease: data from the European Bronchiectasis Registry (EMBARC)","volume":"210","author":"Polverino","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"2026082403352343000_12.4.01529-2025.41","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1513\/AnnalsATS.202302-133OC","article-title":"Quality-of-Life Bronchiectasis Respiratory Symptom Scale predicts the risk of exacerbations in adults with bronchiectasis: a prospective observational study","volume":"21","author":"Gao","year":"2024","journal-title":"Ann Am Thorac Soc"}],"container-title":["ERJ Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/23120541.01529-2025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T10:35:36Z","timestamp":1787567736000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/23120541.01529-2025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":41,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,8,24]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1183\/23120541.01529-2025"],"URL":"https:\/\/doi.org\/10.1183\/23120541.01529-2025","relation":{},"ISSN":["2312-0541"],"issn-type":[{"value":"2312-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,1]]}}}